Skip to content

Cancer Health Center

Font Size

Treatment Option Overview

    Testicular cancer is broadly divided into seminoma and nonseminoma for treatment planning because seminomatous types of testicular cancer are more sensitive to radiation therapy and chemotherapy and are less prone to distant metastases. Moreover, nonseminomas may include teratomatous elements, which tend to be resistant to chemotherapy and often require surgery for cure. By definition, pure seminomas do not contain elements of teratoma. Therefore, surgery plays a larger role in the management of nonseminomas than in the management of seminomas. Nonseminomatous testicular tumors include:

    • Embryonal carcinomas.
    • Yolk sac tumors.
    • Choriocarcinomas.
    • Teratomas.
    • Mixed germ cell tumors.

    An international germ cell tumor prognostic classification has been developed based on a retrospective analysis of 5,202 patients with metastatic nonseminomatous and 660 patients with metastatic seminomatous germ cell tumors.[1] All patients received treatment with cisplatin- or carboplatin-containing therapy as their first chemotherapy course. The prognostic classification, shown below, was agreed on in 1997 by all major clinical trial groups worldwide. It should be used for reporting clinical trial results of patients with germ cell tumors.

    Recommended Related to Cancer

    Clinical Validity

    Clinical validity refers to the predictive value of a test for a given clinical outcome (e.g., the likelihood that cancer will develop in someone with a positive test). It is primarily determined by the sensitivity and specificity with which a test identifies people with a defined clinical condition within a given population. Sensitivity of a test refers to the proportion of people who test positive for a clinical condition among those who actually have the clinical condition; specificity refers...

    Read the Clinical Validity article > >

    A meta-analysis of treatment outcomes for patients with advanced nonseminoma suggested that 5-year survival rates have improved for those patients with a poor prognosis during the period of 1989 to 2004.[2] In addition to improved therapy, the improvement seen in these survival rates could be the result of publication bias, changes in patient selection in reported clinical trials, or more sensitive staging methods that could migrate less-advanced stages to more-advanced stage categories (i.e., stage migration).

    Good Prognosis

    Nonseminoma:

    • Testis/retroperitoneal primary, and
    • No nonpulmonary visceral metastases, and
    • Good markers–all of:
      • Alpha-fetoprotein (AFP) less than 1,000 ng/mL, and
      • Human chorionic gonadotropin (hCG) less than 5,000 IU/mL (1,000 ng/mL), and
      • Lactate dehydrogenase (LDH) less than 1.5 × the upper limit of normal

      56%–61% of nonseminomas

      5-year progression-free survival (PFS) is 89%; 5-year survival is 92%–94%

    Seminoma:

    • Any primary site, and
    • No nonpulmonary visceral metastases, and
    • Normal AFP, any hCG, any LDH

      90% of seminomas

      5-year PFS is 82%; 5-year survival is 86%

      1|2

      Today on WebMD

      Colorectal cancer cells
      A common one in both men and women.
      Lung cancer xray
      See it in pictures, plus read the facts.
       
      sauteed cherry tomatoes
      Fight cancer one plate at a time.
      Ovarian cancer illustration
      Do you know the symptoms?
       
      Jennifer Goodman Linn self-portrait
      Blog
      what is your cancer risk
      HEALTH CHECK
       
      colorectal cancer treatment advances
      Video
      breast cancer overview slideshow
      SLIDESHOW
       
      prostate cancer overview
      SLIDESHOW
      lung cancer overview slideshow
      SLIDESHOW
       
      ovarian cancer overview slideshow
      SLIDESHOW
      Actor Michael Douglas
      Article